Revolution Medicines, Inc. (RVMD) Research

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Market snapshot

Symbol
RVMD
Price
$162.99
Day change
+3.31%
Market cap
$34.7B
P/E ratio
-23.54x
52-week range
34-166.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$165.75

Recent news

  • Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

    Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

  • GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

    GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

  • Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

    U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

Peer companies

  • Ascendis Pharma A/S (ASND)
  • BridgeBio Pharma, Inc. (BBIO)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Exelixis, Inc. (EXEL)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Moderna, Inc. (MRNA)
  • Atrium Therapeutics, Inc. (RNA)

Recent insider activity

  • Mancini Anthony — S-Sale (4615 shares) on 2026-06-16
  • GOLDSMITH MARK A — S-Sale (10020 shares) on 2026-06-16
  • Cislini Jeff — S-Sale (2157 shares) on 2026-06-16
  • Anders Jack — S-Sale (2722 shares) on 2026-06-16
  • Kelsey Stephen Michael — S-Sale (4175 shares) on 2026-06-16

Open Revolution Medicines, Inc. (RVMD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.